| Name | Title | Contact Details |
|---|
Truly Instrument Limited is a Alhambra, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NanoHybrids specializes in research and commercialization of nanotechnology-based products that enhance diagnosis and therapy for cancer and other diseases through enhanced molecular imaging and profiling. Our molecular imaging nanoparticles enhance contrast in vitro and in vivo across multiple biomedical imaging modalities. We are the leading provider of silica-coated gold nanoparticles optimized for photoacoustic (optoacoustic) imaging. With conjugation services we provide nanoparticles with high specificity for targeted cell receptors and tailored to individual applications. Our nanoparticles improve signal strength and allow real time imaging of functional biology. Interested in learning how we are using nanotechnology to drive advances in the life-sciences? Want learn more about our research, products, or services? Contact us, and let`s talk.
NeuroOne Medical Technologies Incorporated (Ticker: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, initially targeting epilepsy. Today, our attention is on the development and commercialization of patented thin-film, cortical electrode technology for intracranial electroencephalography (iEEG) and depth electrodes for stereoelectroencephalography (sEEG) recording of brain activity. The products currently available in these categories have significant limitations such as low recording resolution and high risk of infection. NeuroOne believes our technology can address these unmet needs upon initial commercialization with pipeline technology to advance the field by enabling minimally invasive techniques and all-in-one diagnostic and therapeutic options. While our initial focus is Epilepsy, future applications in Parkinson`s disease, Essential tremors, and Dystonia are within sight. NeuroOne technologies will be presented to a well-defined market, eager for the advancement they bring. There are 188 hospital centers licensed to perform epilepsy surgical procedures in the U.S. The current addressable market opportunity for is approximately $525.6 million. As more patients choose the minimally invasive procedures made available by NeuroOne technology, the future opportunity is estimated to be approximately $14.9 billion with full market penetration.
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 100,000 implanted to date.
Flash Electronics Inc is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.